News2 mins ago
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders USA – English APAC – English
BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING,...
